Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales

Corticosteroids have been used for many years for inflammatory diseases. Mood changes are common during short-term, high-dose, corticosteroid therapy. Virtually no data are available on the mood effects of long-term corticosteroid therapy. To evaluate mood during corticosteroid therapy using standar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of allergy, asthma, & immunology asthma, & immunology, 2004-05, Vol.92 (5), p.500-505
Hauptverfasser: Bolanos, Sandra H., Khan, David A., Hanczyc, Margaret, Bauer, Mark S., Dhanani, Nafisa, Brown, E.S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 505
container_issue 5
container_start_page 500
container_title Annals of allergy, asthma, & immunology
container_volume 92
creator Bolanos, Sandra H.
Khan, David A.
Hanczyc, Margaret
Bauer, Mark S.
Dhanani, Nafisa
Brown, E.S.
description Corticosteroids have been used for many years for inflammatory diseases. Mood changes are common during short-term, high-dose, corticosteroid therapy. Virtually no data are available on the mood effects of long-term corticosteroid therapy. To evaluate mood during corticosteroid therapy using standard clinician-rated and patient-rated measures. Outpatients receiving prednisone therapy (7.5 mg/d for 6 months) and similar controls were enrolled. Current mood was evaluated using the Hamilton Rating Scale for Depression (HRSD), Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale (BPRS), Internal State Scale (ISS), and a diagnostic interview. Twenty patients and 14 controls were enrolled in the study. Depressive symptom severity as evaluated by the HRSD and ISS depression and well-being subscales and global psychiatric symptom severity as evaluated by the BPRS and ISS perceived conflict subscale were greater in patients receiving prednisone than controls. Manic symptom severity as evaluated by the ISS activation subscale but not the YMRS was higher in patients receiving prednisone. Twelve (60%) of 20 corticosteroid-treated patients met diagnostic criteria for a lifetime prednisone-induced mood disorder. Activation subscale scores did not correlate with YMRS scores. Other ISS subscales showed expected correlations with clinician-rated assessments. Mood symptoms and disorders are common in corticosteroid-dependent patients. Unlike short-term prednisone therapy, long-term therapy may be more associated with depressive than manic symptoms based on the clinician-rated assessments. The ISS may be more sensitive to mood symptoms with prednisone than clinician-rated scales.
doi_str_mv 10.1016/S1081-1206(10)61756-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_202779607</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1081120610617565</els_id><sourcerecordid>648170401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-718513aadb88d19ecf287f2c064a8d1f8c9d1361bf2284e374db90c2309692e93</originalsourceid><addsrcrecordid>eNqFkcFuFSEUhomxsbX6CBpiYqKLUQ4zA8PKNI3aJk1cqGvCBaalmYErh1vTl_CZZe6dxu5cAYfv_Af-n5BXwD4AA_HxO7ABGuBMvAP2XoDsRdM_ISfQt13Tda14WvcPyDF5jnjLGINBtM_IMfSgqoo8IX_OED3i7GOhaaRzSo5iMcUjDZFuTQn1Bmn21oe7EK_plOJ1U3yeqU25BJuwHlJwtNz4bLb31ES3tNoUS04T0t-h3DwINbkquz1ipxCDDSauNbRm8viCHI1mQv9yXU_Jzy-ff5xfNFffvl6en101tpOsNBKGHlpj3GYYHChvRz7IkVsmOlML42CVg1bAZuR86HwrO7dRzPKWKaG4V-0peXPQ3eb0a-ex6Nu0y7GO1JxxKZVgskL9AbI5IWY_6m0Os8n3GpheQtD7EPTi8FLah6D72vd6Fd9tZu_-da2uV-DtCpjl22M20QZ8xEnJuILKfTpwvlpxF3zWaKuN1rtQAynapfCfp_wFhrSl1A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>202779607</pqid></control><display><type>article</type><title>Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bolanos, Sandra H. ; Khan, David A. ; Hanczyc, Margaret ; Bauer, Mark S. ; Dhanani, Nafisa ; Brown, E.S.</creator><creatorcontrib>Bolanos, Sandra H. ; Khan, David A. ; Hanczyc, Margaret ; Bauer, Mark S. ; Dhanani, Nafisa ; Brown, E.S.</creatorcontrib><description>Corticosteroids have been used for many years for inflammatory diseases. Mood changes are common during short-term, high-dose, corticosteroid therapy. Virtually no data are available on the mood effects of long-term corticosteroid therapy. To evaluate mood during corticosteroid therapy using standard clinician-rated and patient-rated measures. Outpatients receiving prednisone therapy (7.5 mg/d for 6 months) and similar controls were enrolled. Current mood was evaluated using the Hamilton Rating Scale for Depression (HRSD), Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale (BPRS), Internal State Scale (ISS), and a diagnostic interview. Twenty patients and 14 controls were enrolled in the study. Depressive symptom severity as evaluated by the HRSD and ISS depression and well-being subscales and global psychiatric symptom severity as evaluated by the BPRS and ISS perceived conflict subscale were greater in patients receiving prednisone than controls. Manic symptom severity as evaluated by the ISS activation subscale but not the YMRS was higher in patients receiving prednisone. Twelve (60%) of 20 corticosteroid-treated patients met diagnostic criteria for a lifetime prednisone-induced mood disorder. Activation subscale scores did not correlate with YMRS scores. Other ISS subscales showed expected correlations with clinician-rated assessments. Mood symptoms and disorders are common in corticosteroid-dependent patients. Unlike short-term prednisone therapy, long-term therapy may be more associated with depressive than manic symptoms based on the clinician-rated assessments. The ISS may be more sensitive to mood symptoms with prednisone than clinician-rated scales.</description><identifier>ISSN: 1081-1206</identifier><identifier>EISSN: 1534-4436</identifier><identifier>DOI: 10.1016/S1081-1206(10)61756-5</identifier><identifier>PMID: 15191017</identifier><identifier>CODEN: ANAEA3</identifier><language>eng</language><publisher>McLean, VA: Elsevier Inc</publisher><subject>Adrenal Cortex Hormones - adverse effects ; Affect - drug effects ; Aged ; Biological and medical sciences ; Bipolar Disorder - chemically induced ; Depression - chemically induced ; Female ; Humans ; Immunopathology ; Male ; Medical sciences ; Middle Aged ; Mood Disorders - etiology ; Psychiatric Status Rating Scales ; Reproducibility of Results ; Time Factors</subject><ispartof>Annals of allergy, asthma, &amp; immunology, 2004-05, Vol.92 (5), p.500-505</ispartof><rights>2004 American College of Allergy, Asthma &amp; Immunology</rights><rights>2004 INIST-CNRS</rights><rights>Copyright American College of Allergy and Immunology May 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-718513aadb88d19ecf287f2c064a8d1f8c9d1361bf2284e374db90c2309692e93</citedby><cites>FETCH-LOGICAL-c470t-718513aadb88d19ecf287f2c064a8d1f8c9d1361bf2284e374db90c2309692e93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1081120610617565$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15770291$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15191017$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bolanos, Sandra H.</creatorcontrib><creatorcontrib>Khan, David A.</creatorcontrib><creatorcontrib>Hanczyc, Margaret</creatorcontrib><creatorcontrib>Bauer, Mark S.</creatorcontrib><creatorcontrib>Dhanani, Nafisa</creatorcontrib><creatorcontrib>Brown, E.S.</creatorcontrib><title>Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales</title><title>Annals of allergy, asthma, &amp; immunology</title><addtitle>Ann Allergy Asthma Immunol</addtitle><description>Corticosteroids have been used for many years for inflammatory diseases. Mood changes are common during short-term, high-dose, corticosteroid therapy. Virtually no data are available on the mood effects of long-term corticosteroid therapy. To evaluate mood during corticosteroid therapy using standard clinician-rated and patient-rated measures. Outpatients receiving prednisone therapy (7.5 mg/d for 6 months) and similar controls were enrolled. Current mood was evaluated using the Hamilton Rating Scale for Depression (HRSD), Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale (BPRS), Internal State Scale (ISS), and a diagnostic interview. Twenty patients and 14 controls were enrolled in the study. Depressive symptom severity as evaluated by the HRSD and ISS depression and well-being subscales and global psychiatric symptom severity as evaluated by the BPRS and ISS perceived conflict subscale were greater in patients receiving prednisone than controls. Manic symptom severity as evaluated by the ISS activation subscale but not the YMRS was higher in patients receiving prednisone. Twelve (60%) of 20 corticosteroid-treated patients met diagnostic criteria for a lifetime prednisone-induced mood disorder. Activation subscale scores did not correlate with YMRS scores. Other ISS subscales showed expected correlations with clinician-rated assessments. Mood symptoms and disorders are common in corticosteroid-dependent patients. Unlike short-term prednisone therapy, long-term therapy may be more associated with depressive than manic symptoms based on the clinician-rated assessments. The ISS may be more sensitive to mood symptoms with prednisone than clinician-rated scales.</description><subject>Adrenal Cortex Hormones - adverse effects</subject><subject>Affect - drug effects</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Bipolar Disorder - chemically induced</subject><subject>Depression - chemically induced</subject><subject>Female</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mood Disorders - etiology</subject><subject>Psychiatric Status Rating Scales</subject><subject>Reproducibility of Results</subject><subject>Time Factors</subject><issn>1081-1206</issn><issn>1534-4436</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFuFSEUhomxsbX6CBpiYqKLUQ4zA8PKNI3aJk1cqGvCBaalmYErh1vTl_CZZe6dxu5cAYfv_Af-n5BXwD4AA_HxO7ABGuBMvAP2XoDsRdM_ISfQt13Tda14WvcPyDF5jnjLGINBtM_IMfSgqoo8IX_OED3i7GOhaaRzSo5iMcUjDZFuTQn1Bmn21oe7EK_plOJ1U3yeqU25BJuwHlJwtNz4bLb31ES3tNoUS04T0t-h3DwINbkquz1ipxCDDSauNbRm8viCHI1mQv9yXU_Jzy-ff5xfNFffvl6en101tpOsNBKGHlpj3GYYHChvRz7IkVsmOlML42CVg1bAZuR86HwrO7dRzPKWKaG4V-0peXPQ3eb0a-ex6Nu0y7GO1JxxKZVgskL9AbI5IWY_6m0Os8n3GpheQtD7EPTi8FLah6D72vd6Fd9tZu_-da2uV-DtCpjl22M20QZ8xEnJuILKfTpwvlpxF3zWaKuN1rtQAynapfCfp_wFhrSl1A</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Bolanos, Sandra H.</creator><creator>Khan, David A.</creator><creator>Hanczyc, Margaret</creator><creator>Bauer, Mark S.</creator><creator>Dhanani, Nafisa</creator><creator>Brown, E.S.</creator><general>Elsevier Inc</general><general>American College of Allergy, Asthma, &amp; Immunology</general><general>American College of Allergy and Immunology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20040501</creationdate><title>Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales</title><author>Bolanos, Sandra H. ; Khan, David A. ; Hanczyc, Margaret ; Bauer, Mark S. ; Dhanani, Nafisa ; Brown, E.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-718513aadb88d19ecf287f2c064a8d1f8c9d1361bf2284e374db90c2309692e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adrenal Cortex Hormones - adverse effects</topic><topic>Affect - drug effects</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Bipolar Disorder - chemically induced</topic><topic>Depression - chemically induced</topic><topic>Female</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mood Disorders - etiology</topic><topic>Psychiatric Status Rating Scales</topic><topic>Reproducibility of Results</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bolanos, Sandra H.</creatorcontrib><creatorcontrib>Khan, David A.</creatorcontrib><creatorcontrib>Hanczyc, Margaret</creatorcontrib><creatorcontrib>Bauer, Mark S.</creatorcontrib><creatorcontrib>Dhanani, Nafisa</creatorcontrib><creatorcontrib>Brown, E.S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Annals of allergy, asthma, &amp; immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bolanos, Sandra H.</au><au>Khan, David A.</au><au>Hanczyc, Margaret</au><au>Bauer, Mark S.</au><au>Dhanani, Nafisa</au><au>Brown, E.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales</atitle><jtitle>Annals of allergy, asthma, &amp; immunology</jtitle><addtitle>Ann Allergy Asthma Immunol</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>92</volume><issue>5</issue><spage>500</spage><epage>505</epage><pages>500-505</pages><issn>1081-1206</issn><eissn>1534-4436</eissn><coden>ANAEA3</coden><abstract>Corticosteroids have been used for many years for inflammatory diseases. Mood changes are common during short-term, high-dose, corticosteroid therapy. Virtually no data are available on the mood effects of long-term corticosteroid therapy. To evaluate mood during corticosteroid therapy using standard clinician-rated and patient-rated measures. Outpatients receiving prednisone therapy (7.5 mg/d for 6 months) and similar controls were enrolled. Current mood was evaluated using the Hamilton Rating Scale for Depression (HRSD), Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale (BPRS), Internal State Scale (ISS), and a diagnostic interview. Twenty patients and 14 controls were enrolled in the study. Depressive symptom severity as evaluated by the HRSD and ISS depression and well-being subscales and global psychiatric symptom severity as evaluated by the BPRS and ISS perceived conflict subscale were greater in patients receiving prednisone than controls. Manic symptom severity as evaluated by the ISS activation subscale but not the YMRS was higher in patients receiving prednisone. Twelve (60%) of 20 corticosteroid-treated patients met diagnostic criteria for a lifetime prednisone-induced mood disorder. Activation subscale scores did not correlate with YMRS scores. Other ISS subscales showed expected correlations with clinician-rated assessments. Mood symptoms and disorders are common in corticosteroid-dependent patients. Unlike short-term prednisone therapy, long-term therapy may be more associated with depressive than manic symptoms based on the clinician-rated assessments. The ISS may be more sensitive to mood symptoms with prednisone than clinician-rated scales.</abstract><cop>McLean, VA</cop><pub>Elsevier Inc</pub><pmid>15191017</pmid><doi>10.1016/S1081-1206(10)61756-5</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1081-1206
ispartof Annals of allergy, asthma, & immunology, 2004-05, Vol.92 (5), p.500-505
issn 1081-1206
1534-4436
language eng
recordid cdi_proquest_journals_202779607
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adrenal Cortex Hormones - adverse effects
Affect - drug effects
Aged
Biological and medical sciences
Bipolar Disorder - chemically induced
Depression - chemically induced
Female
Humans
Immunopathology
Male
Medical sciences
Middle Aged
Mood Disorders - etiology
Psychiatric Status Rating Scales
Reproducibility of Results
Time Factors
title Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T17%3A22%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20mood%20states%20in%20patients%20receiving%20long-term%20corticosteroid%20therapy%20and%20in%20controls%20with%20patient-rated%20and%20clinician-rated%20scales&rft.jtitle=Annals%20of%20allergy,%20asthma,%20&%20immunology&rft.au=Bolanos,%20Sandra%20H.&rft.date=2004-05-01&rft.volume=92&rft.issue=5&rft.spage=500&rft.epage=505&rft.pages=500-505&rft.issn=1081-1206&rft.eissn=1534-4436&rft.coden=ANAEA3&rft_id=info:doi/10.1016/S1081-1206(10)61756-5&rft_dat=%3Cproquest_cross%3E648170401%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=202779607&rft_id=info:pmid/15191017&rft_els_id=S1081120610617565&rfr_iscdi=true